Evoke Pharma (NASDAQ:EVOK) Releases Quarterly Earnings Results, Misses Estimates By $0.24 EPS

Evoke Pharma (NASDAQ:EVOK) issued its earnings results on Thursday. The specialty pharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.24), Zacks reports. Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%.

Evoke Pharma Trading Up 4.6 %

Shares of NASDAQ:EVOK traded up $0.17 during mid-day trading on Thursday, reaching $3.85. The stock had a trading volume of 14,049 shares, compared to its average volume of 10,855. The firm has a market cap of $5.72 million, a PE ratio of -0.35 and a beta of 0.12. The firm has a 50 day simple moving average of $4.56 and a two-hundred day simple moving average of $4.72. Evoke Pharma has a twelve month low of $3.44 and a twelve month high of $12.32.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Evoke Pharma in a research note on Wednesday. They issued a “sell” rating on the stock.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.